1. Introduction {#sec1}
===============

Decisive routes for the syntheses and expansion of novel drugs are demonstrated via targeting the metabolic pathways. Nucleoside analogues create a significant class of antimetabolic agents used in the treatment of tumors, in addition to numerous viral diseases.^[@ref1],[@ref2]^ Pyrimidinethione nucleosides have major roles in therapeutic chemistry. Numerous pyrimidinethione products are planned to target the key stages in cellular use.^[@ref3]^ They have fundamental effects in medicinal chemistry and broad uses in biochemistry. Several of those compounds are measured as possible chemotherapeutic agents that have an abundant influence on recent medicinal research. Nucleosides comprising sulfur establish a class of nucleosides present in natural nucleic acids.^[@ref4]^ Among these compounds are some derivatives of 2-thiouridine S2U ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) that occupy the first anticodon position in the transfer RNAs specific for some amino acids, 2-thiouridines importantly provide translational regulation via codon--anticodon connections.^[@ref5]^ Many approaches for the synthesis of several categories of pyrimidine nucleoside derivatives have been settled.^[@ref6],[@ref7]^ The main value of the pyrimidinethiones prompted their effectiveness against a wide range of dangerous diseases such as microbial, malignancies, cancer, and many antiviral diseases. Accordingly, modern ideas about choosing and designing new compounds have been illustrated. Hence, well-known procedures have been established to develop and discover additional effective drugs.^[@ref8],[@ref9]^

![2-Thiouridine (S2U).](ao0c01537_0002){#fig1}

As a part of our up-to-date plan aimed toward discovering synthetic methods for the preparation of S-glycosylated derivatives of heterocyclic nitrogen bases, we have lately described the synthesis and antiviral activity of a series of heterocyclic S-glycosides that have interesting cytotoxic activity such as pyridine S-glycosides,^[@ref10],[@ref11]^ pyrimidine S-glycosides,^[@ref12],[@ref13]^ imidazole S-glycosides,^[@ref14]^ oxadiazole S-glycosides,^[@ref15]^ pyrazole S-glycosides,^[@ref16],[@ref17]^ triazole S-glycosides,^[@ref18]^ thiazole S-glycosides,^[@ref19]^ and purine S-glycosides.^[@ref20],[@ref21]^ Similar pyrimidine and purine thioglycosides were previously reported.^[@ref22]^ We found that the dihydropyridine S-glycosides presented a strong P-glycoprotein antagonist effect and activity against human cancer cells.^[@ref23]^ In the light of these results and our previous research,^[@ref24]^ the purpose of the present work was to design, prepare, and explore the antiviral activity of pyrimidines linked to sugar moieties through S-glycosidic linkage formation.

2. Results and Discussion {#sec2}
=========================

It has been found that aromatic amines **1a**--**d** react with ethyl cyanoacetate **2** to give the corresponding acetanilide derivatives **3a**--**d**.^[@ref25]^

The synthesis of our desired pyrimidine thioglycosides was carried out by reaction of acetanilide derivatives **3a**--**d** and carbon disulfide in a basic medium (sodium ethoxide) using a simple one-step procedure to give the sodium 2-cyano-3-oxo-3-(arylamino)prop-1-ene-1,1-bis(thiolate) salts **4a**--**d** in high yields ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Refluxing of compound **4** with its corresponding urea **6** in boiling ethanol for 8 h results in sodium 6-amino-5-aryl-2-oxo-1,2-dihydropyrimidine-4-thiolate derivatives **7a**--**d** in good yields. Acidification of the latter has led to the creation of the corresponding 3-mercaptopyrimidines **8a**--**d**. Compounds **8a**--**d** could also be synthesized through the reaction of ketene dithioles **5a**--**d** with urea in refluxing ethanol--NaOH. The structures of compounds **8** have been verified by using spectral and chemical measurements. Thus, the ^1^H NMR spectrum of **8a** revealed a signal at δ 13.51 ppm attributed to an SH group, and its ^13^C NMR spectrum exhibited signals at δ 159.46 and 164.81 ppm attributed to two carbonyl groups. Stirring of compounds **7a**--**d** with the acetylated α-[d]{.smallcaps}-gluco- and galacto-pyranosyl bromides **9a,b** in dimethylformamide (DMF) at ambient temperature afforded in great yields the corresponding pyrimidine S-glycosides **10a**--**h** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). It has been proposed that the cis-(α) sugars interact via a simple SN^2^ reaction to give the β-glycoside products.^[@ref26]^ Structures of 10a--h were characterized using the spectral data \[^13^C NMR, ^1^H NMR, and infrared (IR)\]. For example, in the ^1^H NMR spectrum of the **10a** anomeric proton, a doublet was found at δ 5.38 ppm with a spin--spin coupling constant of 9.6 Hz, demonstrating the β-configuration. The other six protons of glucose were resonated at δ 3.98--4.93 ppm. Compounds **10a**--**h** can also be synthesized by the reaction of the pyrimidine-4-thioles **8a**--**d** with halo sugars **9** in DMF--sodium hydride at room temperature. When glycosides **10a**--**h** were reacted with NH~3~--MeOH at room temperature for 10 min, the deacetylated derivatives **11a**--**h** were obtained in good yields ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The structures were characterized using the spectral data and elemental analysis. Thus, in the ^1^H NMR spectrum of the **11a** anomeric proton a doublet was detected at δ 4.32 (*J*~1′,2′~ = 9.1 Hz), signifying only the β-[d]{.smallcaps}-configuration, which was proved using the ^13^C NMR spectrum, which exhibited a signal at δ 82.61 corresponding to C-1′. The signals at δ 62.54, 70.63, 73.26, 76.67, and 80.21 were attributed to C-6′, C-5′, C-4′, C-3′, and C-2′.

![Synthesis of Pyrimidine Thioglycosides **10a**--**h**](ao0c01537_0005){#sch1}

![Synthesis of Free Pyrimidine Thioglycosides **11a**--**h**](ao0c01537_0006){#sch2}

3. Conclusions {#sec3}
==============

A novel pathway for the synthesis of an important new class of thiopyrimidines and their corresponding thioglycoside analogues has been established. The results presented a new, simple, and clear route for the preparation of the cytosine nucleoside analogues. The ambient temperature reaction conditions, clean and excellent yield reaction products, render this method as a more efficient method among the existing preparation methods for the synthesis of pyrimidine thioglycosides. Further research on the application of this preparation method for the synthesis of other biologically remarkable active glycosides needs to be carried out. These thioglycosides can be used as preliminary compounds for the preparation of other remarkable carbohydrates.

3.1. Antiviral Activity {#sec3.1}
-----------------------

The antiviral activity of the synthesized compounds was evaluated with respect to H5N1 influenza virus strain A/Egypt/M7217B/2013 utilizing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity (TC50) and plaque reduction assays exploring inhibition and cytotoxicity percentage values. The accumulated inhibition activities and cytotoxicity data ([Table[1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) indicated that most of the compounds demonstrated dose-dependent inhibition behavior.

![Cytotoxicity of compounds **8a**, **8b**, **8c**, **8d**, **10a**, **10b**, **10c**, **10d**, **10e**, **10f**, **10g**, and **10h** at concentrations 0.25 and 0.125 μmol/mL.](ao0c01537_0003){#fig2}

![Cytotoxicity of compounds **11a**, **11b**, **11c**, **11d**, **11e**, **11f**, **11g**, and **11h** at concentrations 0.25 and 0.125 μmol/mL.](ao0c01537_0004){#fig3}

###### Antiviral Activity of the Tested Compounds Measured Using the Plaque Reduction Assay

  comp. no.   concentration (μmol/mL)   initial viral count   viral count PFU/mL   inhibition %   comp. no.   concentration (μmol/mL)   initial viral count   viral count PFU/mL   inhibition %
  ----------- ------------------------- --------------------- -------------------- -------------- ----------- ------------------------- --------------------- -------------------- --------------
  **8a**      0.125                     3.1 × 10^6^           6 × 10^6^            48.33          **10g**     0.125                     2.2 × 10^6^           6 × 10^6^            63.33
              0.25                      3.8 × 10^6^           6 × 10^6^            36.67                      0.25                      2.0 × 10^6^           6 × 10^6^            66.67
  **8b**      0.125                     6.0 × 10^6^           6 × 10^6^            0              **10h**     0.125                     3.0 × 10^6^           6 × 10^6^            50
              0.25                      3.0 × 10^6^           6 × 10^6^            50                         0.25                      1.3 × 10^6^           6 × 10^6^            75
  **8c**      0.125                     3.3 × 10^6^           6 × 10^6^            45             **11a**     0.125                     3.1 × 10^6^           6 × 10^6^            48.33
              0.25                      4.0 × 10^6^           6 × 10^6^            33.33                      0.25                      2.5 × 10^6^           6 × 10^6^            58.33
  **8d**      0.125                     3.0 × 10^6^           6 × 10^6^            50             **11b**     0.125                     2.0 × 10^6^           6 × 10^6^            66.67
              0.25                      3.2 × 10^6^           6 × 10^6^            46.67                      0\.                       2.2 × 10^6^           6 × 10^6^            63.33
  **10a**     0.125                     3.3 × 10^6^           6 × 10^6^            45             **11c**     0.125                     3.4 × 10^6^           6 × 10^6^            43.33
              0.25                      2.4 × 10^6^           6 × 10^6^            60                         0.25                      3.2 × 10^6^           6 × 10^6^            46.67
  **10b**     0.125                     4.6 × 10^6^           6 × 10^6^            20             **11d**     0.125                     4.0 × 10^6^           6 × 10^6^            33.33
              0.25                      1.9 × 10^6^           6 × 10^6^            68.33                      0.25                      2.4 × 10^6^           6 × 10^6^            60
  **10c**     0.125                     4.5 × 10^6^           6 × 10^6^            25             **11e**     0.125                     2.0 × 10^6^           6 × 10^6^            65.67
              0.25                      2.5 × 10^6^           6 × 10^6^            58.33                      0.25                      2.2 × 10^6^           6 × 10^6^            63.33
  **10d**     0.125                     3.4 × 10^6^           6 × 10^6^            43.33          **11f**     0.125                     3.5 × 10^6^           6 × 10^6^            41.67
              0.25                      2.0 × 10^6^           6 × 10^6^            66.67                      0.25                      1.7 × 10^6^           6 × 10^6^            71.67
  **10e**     0.125                     3.0 × 10^6^           6 × 10^6^            50             **11g**     0.125                     3.6 × 10^6^           6 × 10^6^            40
              0.25                      1.9 × 10^6^           6 × 10^6^            68.33                      0.25                      2.5 × 10^6^           6 × 10^6^            58.33
  **10f**     0.125                     2.0 × 10^6^           6 × 10^6^            66.67          **11h**     0.125                     3.4 × 10^6^           6 × 10^6^            43.33
              0.25                      1.9 × 10^6^           6 × 10^6^            85.33                      0.25                      2.0 × 10^6^           6 × 10^6^            66.67

All tested compounds exhibited the highest to moderate activity toward H5N1 virus. Attachment of sugar moieties, especially protected sugars, to the substituted 2-oxo-*N*-phenyl-1,2-dihydropyrimidine-5-carboxamide derivatives (compounds **10a**--**h**) demonstrated higher inhibition activity than unprotected sugar (compounds **11a**--**h**) against H5N1 virus. However, pyrimidine derivatives incorporated with galacto (compounds **10e**--**h**, **11e**--**h**) showed higher inhibition activity than its gluco analogues (compounds **10a**--**d**, **11a**--**d**). Most active compounds tested in this study contained the 4-chlorophenyl moiety and methoxyphenyl at the 4-position, while compounds possessing methyl phenyl and phenyl rings exhibited lower antiviral activity. On the other hand, compounds pyrimidine 4-mercapto derivatives (compounds **8a**--**d**) demonstrated moderate anti-H5N1 activity.

4. Experimental Section {#sec4}
=======================

All melting points were measured on an Electrothermal 9100 digital melting point apparatus. The ^1^H NMR and ^13^C NMR spectra were measured on a JEOL-500 MHz spectrometer in DMSO-*d*~6~ or CDCl~3~ using Si(CH~3~)~4~ as an internal standard at the National Research Centre, Cairo, Egypt. Potential cytotoxicity assay of the newly synthesized compounds was evaluated at the Center of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre (NRC), Dokki, Cairo 12622, Egypt. Elemental analyses were carried out at the Microanalytical Unit, Faculty of Science, Cairo University, Cairo, Egypt. Progress of the reactions was monitored by thin-layer chromatography (TLC) using aluminum sheets coated with silica gel *F*~254~ plates with a layer thickness of 0.25 nm (Merck). By viewing under a short-wavelength UV lamp, effective detection can be achieved. Compounds (**4a**--**d**, **5a**--**d**) were prepared following our reported procedures.^[@ref25],[@ref27]^

4.1. General Procedure for the Synthesis of Sodium Pyrimidine Thiolates (**7a**--**d**) {#sec4.1}
---------------------------------------------------------------------------------------

### 4.1.1. Method A {#sec4.1.1}

An ethanolic solution of urea (10 mmol) was added dropwise for 30 min to sodium 2-cyano-3-oxo-3-(arylamino)prop-1-ene-1,1-bis(thiolates) **4a**--**d** (10 mmol) dissolved in 10 mL of absolute ethanol, and the reaction mixture was heated for 8 h. After the reaction was completed (monitored by TLC), the mixture was cooled and then poured into ice water. The obtained solid was filtered, dried, and recrystallized from ethanol to provide compounds **7a**--**d**.

### 4.1.2. Method B {#sec4.1.2}

To a solution of compounds **8a**--**d** (10 mmol) in ethanol, sodium hydroxide (10 mmol) was added, and the mixture was stirred at 50 °C for 1 h and allowed to cool to room temperature. The formed solid product was collected by filtration and recrystallized from an appropriate solvent.

#### 4.1.2.1. Sodium-6-amino-2-oxo-5-(phenylcarbamoyl)-1,2-dihydropyrimidine-4-thiolate (**7a**) {#sec4.1.2.1}

White solid; (EtOH); yield (85%); mp \> 300 °C; IR (KBr, cm^--1^) υ: 3373 (NH~2~), 3266 (NH), 3029 (CH aromatic), 1682 (C=O), and 1592 (C=N). C~11~H~9~N~4~NaO~2~S (284.27).

#### 4.1.2.2. Sodium 6-Amino-5-(4-chlorophenylcarbamoyl)-2-oxo-1,2-dihydropyrimidine-4-thiolate (**7b**) {#sec4.1.2.2}

White solid; (EtOH); yield (82%); mp \> 300 °C; IR (KBr, cm^--1^) υ: 3356, 3342 (NH~2~), 3251 (NH), 3036 (CH aromatic), 2972 (CH), 1695 (C=O), 1654 (CO), 1600 (C=N). C~11~H~8~ClN~4~NaO~2~S (318.71).

#### 4.1.2.3. Sodium 6-Amino-2-oxo-5-(*p*-tolylcarbamoyl)-1,2-dihydropyrimidine-4-thiolate (**7c**) {#sec4.1.2.3}

White solid; (EtOH); yield (95%); mp \> 300 °C; IR (KBr, cm^--1^) υ: 3351, 3346, (NH~2~), 3276 (NH), 3252 (NH), 2921 (CH), 1696 (C=O), 1677 (CO), 1594 (C=N). C~12~H~11~N~4~NaO~2~S (298.30).

#### 4.1.2.4. Sodium-6-amino-5-(4-methoxyphenylcarbamoyl)-2-oxo-1,2-dihydropyrimidine-4-thiolate (**7d**) {#sec4.1.2.4}

White solid; (EtOH); yield (79%); mp \> 300 °C; IR (KBr, cm^--1^) υ: 3356 (NH~2~), 3267 (NH), 3032 (CH aromatic), 2938 (CH), 1682 (C=O), 1648 (CO), 1602 (C=N). C~12~H~11~N~4~NaO~3~S (314.30).

4.2. General Procedure for the Synthesis of Pyrimidine Thiols (**8a**--**d**) {#sec4.2}
-----------------------------------------------------------------------------

### 4.2.1. Method A {#sec4.2.1}

A mixture of sodium 2-cyano-3-oxo-3-(arylamino)prop-1-ene-1,1-bis(thiolates) **5a**--**d** (10 mmol) and urea (10 mmol) in ethanolic sodium hydroxide (10 mL) was refluxed for 3 h. After the reaction was completed, the reaction mixture was concentrated and cooled, and the residue was poured into ice water, collected by filtration, dried, and recrystallized from ethanol producing compounds **8a**--**d**.

### 4.2.2. Method B {#sec4.2.2}

To an aqueous a solution of compound **7a**--**d** (10 mmol), three drops of HCl (36%) were added at room temperature (25 °C) with stirring, and the obtained white solid was filtered off and crystallized from ethanol to give **8a**--**d**.

#### 4.2.2.1. 6-Amino-4-mercapto-2-oxo-*N*-phenyl-1,2-dihydropyrimidine-5-carboxamide (**8a**) {#sec4.2.2.1}

White solid; (EtOH); yield (85%); mp 254 °C; IR (KBr, cm^--1^) υ: 3388 (NH~2~), 3272 (NH), 3261 (NH), 3035 (CH aromatic), 1682 (C=O), 1646 (CO), 1595 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.26 (s, D~2~O exch., 2H, NH~2~), 7.32--7.63 (m, 5H, C~6~H~5~), 10.64 (s, D~2~O exch., 1H, NH), 11.28 (s, D~2~O exch., 1H, NH), 13.51 (s, D~2~O exch., 1H, SH); ^13^C NMR: δ 81.41 (C-5), 124.63 (2C, Ar--C), 126.82 (Ar--C), 130.64 (2C,Ar--C), 140.54 (Ar--C), 159.46 (CO), 164.81 (CO), 167.26 (C-4),169.70 (C-6). Anal. Calcd for C~11~H~10~N~4~O~2~S (262.29): C, 50.37; H, 3.84; N, 21.36; S, 12.23. Found: C, 50.25; H, 3.76; N, 21.30; S, 12.18%.

#### 4.2.2.2. 6-Amino-*N*-(4-chlorophenyl)-4-mercapto-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**8b**) {#sec4.2.2.2}

White solid; (EtOH); yield (80%); mp 248 °C; IR (KBr, cm^--1^) υ: 3372 (NH~2~), 3260 (NH), 3252 (NH), 3038 (CH aromatic), 1689 (C=O), 1649 (CO), 1598 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.82 (s, D~2~O exch., 2H, NH~2~), 7.35--7.84 (m, 4H, C~6~H~4~), 10.85 (s, D~2~O exch., 1H, NH), 11.46 (s, D~2~O exch., 1H, NH), 13.47 (s, D~2~O exch., 1H, SH); ^13^C NMR: δ 82.32 (C-5), 124.86 (2C, Ar--C), 131.45 (2C, Ar--C), 138.74 (Ar--C), 139.83 (Ar--C), 160.57(CO), 163.76 (CO), 168.42 (C-4), 170.37 (C-6). Anal. Calcd for C~11~H~9~ClN~4~O~2~S (296.73): C, 44.52; H, 3.06; Cl, 11.95; N, 18.88; S, 10.81. Found: C, 44.40; H, 3.16; Cl, 11.90; N, 18.82; S, 10.65%.

#### 4.2.2.3. 6-Amino-4-mercapto-2-oxo-*N*-*p*-tolyl-1,2-dihydropyrimidine-5-carboxamide (**8c**) {#sec4.2.2.3}

White solid; (EtOH); yield (85%); mp 234 °C; IR (KBr, cm^--1^) υ: 3353 (NH~2~), 3247 (NH), 3235 (NH), 3029 (CH aromatic), 1683 (C=O), 1655 (CO), 1601 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.46 (s, 3H, CH~3~), 6.69 (s, D~2~O exch., 2H, NH~2~), 7.34--7.56 (m, 4H, C~6~H~4~), 10.23 (s, D~2~O exch., 1H, NH), 10.96 (s, D~2~O exch., 1H, NH), 13.26 (s, D~2~O exch., 1H, SH); ^13^C NMR: δ 23.15 (CH~3~), 80.24 (C-5), 123.63 (2C, Ar--C), 133.26 (2C, Ar--C), 136.45 (Ar--C), 138.37 (Ar--C), 159.84 (CO), 164.34 (CO), 167.65 (C-4), 169.89 (C-6). Anal. Calcd for C~12~H~12~N~4~O~2~S (276.31): C, 52.16; H, 4.38; N, 20.28; S, 11.60. Found: C, 52.13; H, 4.27; N, 20.17; S, 11.54%.

#### 4.2.2.4. 6-Amino-4-mercapto-*N*-(4-methoxyphenyl)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**8d**) {#sec4.2.2.4}

White solid; (EtOH); yield (79%); mp 222 °C; IR (KBr, cm^--1^) υ: 3373 (NH~2~), 3235 (NH), 3217 (NH), 3039 (CH aromatic), 1672 (C=O), 1651 (CO), 1599 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.95 (s, 3H, CH~3~), 6.82 (s, D~2~O exch., 2H, NH~2~), 7.23--7.57 (m, 4H, C~6~H~4~), 10.54 (s, D~2~O exch., 1H, NH), 11.65 (s, D~2~O exch., 1H, NH), 13.17 (s, D~2~O exch., 1H, SH); ^13^C NMR: δ 58.26 (CH~3~), 85.14 (C-5), 122.45 (2C, Ar--C), 126.23 (2C, Ar--C), 132.28 (Ar--C), 156.41 (CO), 163.35 (Ar--C), 165.83 (CO), 168.16 (C-4), 170.22 (C-6). Anal. Calcd for C~12~H~12~N~4~O~3~S (292.31): C, 49.31; H, 4.14; N, 19.17; S, 10.97. Found: C, 49.19; H, 4.8; N, 19.10; S, 10.83%.

4.3. General Procedure for the Synthesis of Pyrimidine Thioglycosides (**10a**--**h**) {#sec4.3}
--------------------------------------------------------------------------------------

### 4.3.1. Method A {#sec4.3.1}

2,3,4,6-Tetra-O-acetyl-α-[d]{.smallcaps}-gluco- or galacto pyranosyl bromide **9a**,**b** (10 mmol) dissolved in dry DMF, which was dropped gradually within 30 min, was added to a solution of compounds **7a**--**d** (10 mmol) in 20 mL of DMF, and the reaction mixture was stirred at room temperature till completion of the reaction (monitored by TLC). Then, the mixture was poured into ice water, and the resulting precipitate was collected by filtration, dried, and crystallized from an appropriate solvent system to give compounds **10a**--**h**.

### 4.3.2. Method B {#sec4.3.2}

Sodium hydride (15 mmol) was added slowly to a 50 mL flask containing the solution of compound **8a**--**d** (10 mmol) in DMF (20 mL), and the reaction mixture was stirred for 30 min at room temperature. Then, a solution of 2,3,4,6-tetra-O-acetyl-α-[d]{.smallcaps}-gluco- or galacto-pyranosyl bromide **9a**,**b** (10 mmol) in DMF was added dropwise to the reaction mixture for 30 min, and the reaction mixture was stirred at room temperature until completion (monitored by TLC). After the reaction was completed, the reaction mixture was poured into ice water and the yielded product was collected by filtration, dried, and crystallized from an appropriate solvent to give compounds **10a**--**d**.

#### 4.3.2.1. 6-Amino-4-(2′,3′,4′,6′-tetra-O-acetyl-β-[d]{.smallcaps}-glucopyranosylthio2-oxo-*N*-phenyl-1,2-dihydropyrimidine-5-carboxamide(**10a**) {#sec4.3.2.1}

White solid; (EtOH), yield (88%) (method A), (80%) (method B), mp 228 °C; IR (KBr, cm^--1^) υ: 3335 (NH~2~), 3224 (NH), 3048 (CH aromatic), 2936 (CH), 1762 (C=O), 1682 (C=O), 1601 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.90, 1.95, 1.99, 2.02 (4s, 12H, 4 × OAc), 3.98--4.00 (m, 2H, 2H-6′), 4.15--4.16 (m, 1H, H-5′), 4.86 (t, 1H, *J*~4′--3′~ = 10.5 Hz, *J*~4′--5′~ = 9.1 Hz, H-4′), 4.96 (t, 1H, *J*~3′--2′~ = 9.6 Hz, *J*~3′--4′~ = 10.5 Hz, H-3′), 4.93 (t, 1H, *J*~2′--1′~ = 9.6 Hz, *J*~2′--3′~ = 9.5 Hz, H-2′), 5.38 (d, 1H, *J*~1′--2′~ = 9.6 Hz, H-1′), 6.75 (s, D~2~O exch., 2H, NH~2~), 7.19--7.45 (m, 5H, C~6~H~5~), 8.84 (s, D~2~O exch., 1H, NH), 10.43 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 22.35 (4 × CH~3~), 62.43 (C-6′), 67.86 (C-5′), 70.19 (C-4′), 73.42 (C-3′), 77.47 (C-2′), 79.68 (C-1′), 89.41 (C-5), 124.26 (2C, Ar--C), 131.37 (Ar--C), 132.54 (2C, Ar--C), 143.65 (Ar--C), 162.28 (C=O), 166.53 (C=O), 168.17 (C-4), 169.79 (C-6), 173.15 (4C=O). Anal. Calcd for C~25~H~28~N~4~O~11~S (592.58): C, 50.67; H, 4.76; N, 9.45; S, 5.41. Found: C, 50.58; H, 4.66; N, 9.32; S, 5.45.%.

#### 4.3.2.2. 6-Amino-*N*-(4-chlorophenyl)-4-(2′,3′,4′,6′-tetra-O-acetyl-β-[d]{.smallcaps}-glucopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide(**10b**) {#sec4.3.2.2}

White solid; (EtOH), yield (80%) (method A), (78%) (method B), mp 248 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.98.1.99, 2.02, 2.06 (4s, 12H, 4 × OAc), 3.87--3.88 (m, 2H, 2H-6′), 4.21--4.24 (m, 1H, H-5′), 4.47 (t,1H, *J*~4′--3′~ = 9.1 Hz, *J*~4′--5′~ = 9.2 Hz, H-4′), 4.53 (t, 1H, *J*~3′--2′~ = 8.8 Hz, *J*~3′--4′~ = 9.1 Hz, H-3′), 4.64 (t, 1H, *J*~2′--1′~ = 10.8 Hz, *J*~2′--3′~ = 8.8 Hz, H-2′), 5.52 (d, 1H, *J*~1′--2′~ = 10.8 Hz, H-1′), 7.21 (s, D~2~O exch., 2H, NH~2~), 7.42--7.78 (m, 4H, C~6~H~4~), 10.84 (s, D~2~O exch., 1H, NH), 11.57 (s, D2O exch., 1H, NH); ^13^C NMR: δ 22.59 (4 × CH~3~), 62.46 (C-6′), 66.41 (C-5′), 69.45 (C-4′), 72.13 (C-3′), 76.44 (C-2′), 79.24 (C-5), 81.34 (C-1′), 123.64 (2C, Ar--C), 126.29 (2C, Ar--C), 129.12 (Ar--C), 138.11 (Ar--C), 159.68 (C=O), 164.26 (C=O), 167.21 (C-4), 169.15 (C-6), 172.67 (4C=O). Anal. Calcd for C~25~H~27~ClN~4~O~11~S (627.02): C, 47.89; H, 4.34; Cl, 5.65; N, 8.94; S, 5.11. Found: C, 47.77; H, 4.26; Cl, 5.58; N, 8.86; S, 5.10%.

#### 4.3.2.3. 6-Amino-4-(2′,3′,4′,6′-tetra-O-acetyl-β-[d]{.smallcaps}-glucopyranosylthio)-2-oxo-*N*-*p*-tolyl-1,2-dihydropyrimidine-5-carboxamide (**10C**) {#sec4.3.2.3}

White solid; (EtOH), yield (86%) (method A), (82%) (method B), mp 264 °C; ^1^H NMR (500 MHz, CDCl3): δ 1.97, 2.01, 2.02, 2.04 (4s, 12H, 4 × OAc), 2.32 (s, 3H, CH~3~), 3.97--3.99 (m, 1H, H-5′), 4.03 (d, 1H, *J*~6′--5′~ = 3.2 Hz H-6′), 4.16 (dd, 1H, *J*~6″--5′~ = 2.5 Hz, *J*~6″--6′~ = 12.4 Hz, H-6″), 5.14 (t, 1H, *J*~4′--3′~ = 8.9 Hz, *J*~4′--5′~ = 8.6 Hz, H-4′), 5.22 (t, 1H, *J*~3′--2′~ = 9.7 Hz, *J*~3′--4′~ = 8.9 Hz, H-3′), 5.30 (t, 1H, *J*~2′--1′~ = 9.7 Hz, *J*~2′--3′~ = 9.7 Hz, H-2′), 5.59 (d, 1H, *J*~1′--2′~ = 9.7 Hz H-1′), (s, D~2~O exch., 2H, NH~2~), 7.14 (d, 2H, *J* = 8.6 Hz, Ar--H), 7.45 (d, 2H, *J* = 7.7 Hz, Ar--H), 8.37 (s, D~2~O exch., 1H, NH), 9.22 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 20.71 (4 × CH~3~), 29.41(CH~3~), 61.81 (C-6′), 68.08 (C-5′), 70.22 (C-4′), 74.21 (C-3′), 75.64 (C-2′), 83.84 (C-1′), 91.62 (C-5), 120.40 (2C, Ar--C), 129.69 (2C, Ar--C), 134.52 (Ar--C), 135.31 (Ar--C), 152.71 (C=O), 156.82 (C=O), 166.15 (C-4), 169.51 (C-6), 176.24 (4C=O). Anal. Calcd for C~26~H~30~N~4~O~11~S (606.60): C, 51.48; H, 4.98; N, 9.24; S, 5.29. Found: C, 51.36; H, 4.90; N, 9.18; S, 5.22%.

#### 4.3.2.4. 6-Amino-*N*-(4-methoxyphenyl)-4-(2′,3′,4′,6′-tetra-1-acetyl-β-[d]{.smallcaps}-glucopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**10d**) {#sec4.3.2.4}

White solid; (EtOH), yield (85%) (method A), (62%) (method B), mp 254 °C; IR (KBr, cm^--1^) υ: 3346 (NH~2~), 3234 (NH), 3028 (CH aromatic), 2986 (CH), 1752 (C=O), 1675 (C=O), 1596 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.97, 1.98, 2.03, 2.08 (4s, 12H, 4 × OAc), 3.87 (s, 3H, OCH~3~), 3.92--3.94 (m, 2H, 2H-6′), 4.28--4.31 (m, 1H, H-5′), 4.46 (t, 1H, *J*~4′--3′~ = 9.2 Hz, *J*~4′--5′~ = 9.3 Hz, H-4′), 4.94 (t, 1H, *J*~3′--2′~ = 8.6 Hz, *J*~3′--4′~ = 8.6 Hz, H-3′), 4.82 (t, 1H, *J*~2′--1′~ = 9.4 Hz, *J*~2′--3′~ = 9.2 Hz, H-2′), 5.65 (d, 1H, *J*~1′--2′~ = 9.4 Hz, H-1′), 7.21 (s, D~2~O exch., 2H, NH~2~), 7.38--7.61 (m, 4H, C~6~H~4~), 8.82 (s, D~2~O exch., 1H, NH), 9.87(s, D~2~O exch., 1H, NH); ^13^C NMR: δ 22.28 (4 × CH~3~), 56.74 (CH3), 62.45 (C-6′), 67.26 (C-5′), 71.63 (C-4′), 73.41 (C-3′), 77.54 (C-2′), 79.42 (C-1′), 92.61 (C-5), 121.21 (2C, Ar--C), 124.46 (2C, Ar--C), 133.67 (Ar--C), 160.31 (C=O), 162.14 (Ar--C), 163.38 (C=O), 164.51 (C-4), 166.18 (C-6), 173.24 (4C=O). Anal. Calcd for C~26~H~30~N~4~O~12~S (622.60): C, 50.16; H, 4.86; N, 9.00; S, 5.15. Found: C, 50.10; H, 4.78; N, 9.04; S, 5.12%.

#### 4.3.2.5. 6-Amino-4-(2′,3′,4′,6′-tetra-O-acetyl-β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-*N*-phenyl-1,2-dihydropyrimidine-5-carboxamide(**10e**) {#sec4.3.2.5}

White solid; (EtOH), yield (88%) (method A), (82%) (method B), mp 258 °C; IR (KBr, cm^--1^) υ: 3275 (NH~2~), 3228 (NH), 3035 (CH aromatic), 2918 (CH), 1756 (C=O), 1685 (C=O), 1602 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.97, 1.98, 2.01, 2.06 (4s, 12H, 4 × OAc), 3.99--4.01 (m, 2H, 2H-6′), 4.16--4.23 (m, 1H, H-5′), 4.42 (t, 1H, *J*~4′--3′~ = 9.1 Hz, *J*~4′--5′~ = 3.3 Hz, H-4′), 4.61 (t, 1H, *J*~3′--2′~ = 9.3 Hz, *J*~3′--4′~ = 3.6 Hz, H-3′), 4.81 (t, 1H, *J*~2′--1′~ = 11.3 Hz, *J*~2′--3′~ = 9.3 Hz, H-2′), 5.26 (d, 1H, *J*~1′--2′~ = 11.3 Hz, H-1′), 6.72 (s, D~2~O exch., 2H, NH~2~), 7.34--7.75 (m, 5H, C~6~H~5~), 10.66 (s, D~2~O exch., 1H, NH), 11.37 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 22.16 (4 × CH~3~), 62.57 (C-6′), 66.42 (C-5′), 69.53 (C-4′), 70.61 (C-3′), 76.36 (C-2′), 78.23 (C-1′), 92.17 (C-5), 122.35 (2C, Ar--C), 132.14 (Ar--C), 133.62 (2C, Ar--C), 141.83 (Ar--C), 163.42 (C=O), 165.15 (C=O), 168.41(C-4), 169.14 (C-6), 172.26 (4C=O). Anal. Calcd for C~25~H~28~N~4~O~11~S (592.58): C, 50.67; H, 4.76; N, 9.45; S, 5.41. Found: C, 50.58; H, 4.66; N, 9.32; S, 5.45%.

#### 4.3.2.6. 6-Amino-*N*-(4-chlorophenyl)-4-(2′,3′,4′,6′-tetra-O-acetyl-β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**10f**) {#sec4.3.2.6}

White solid; (EtOH), yield (86%) (method A), (83%) (method B), mp 259--260 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.97.1.98, 2.01, 2.04 (4s, 12H, 4 × OAc), 3.98--4.01 (m, 2H, 2H-6′), 4.26--4.29 (m, 1H, H-5′), 4.38 (t, 1H, *J*~4′--3′~ = 3.5 Hz, *J*~4′--5′~ = 3.6 Hz, H-4′), 4.42 (t, 1H, *J*~3′--2′~ = 9.2 Hz, *J*~3′--4′~ = 3.7 Hz, H-3′), 4.61 (t, 1H, *J*~2′--1′~ = 10.4 Hz, *J*~2′--3′~ = 8.8 Hz, H-2′), 5.61 (d, 1H, *J*~1′--2′~ = 10.4 Hz, H-1′), 6.67 (s, D~2~O exch., 2H, NH~2~), 7.43--7.76 (m, 4H,C~6~H~4~), 10.57 (s, D~2~O exch., 1H, NH) 11.38 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 22.33 (4 × CH~3~), 62.52 (C-6′), 67.52 (C-5′), 69.71 (C-4′), 73.26 (C-3′), 74.68 (C-2′), 79.24 (C-1′), 90.16 (C-5), 124.36 (2C, Ar--C), 125.62 (2C, Ar--C), 130.14 (Ar--C), 139.65 (Ar--C), 162.16 (C=O), 164.52 (C=O), 166.32 (C-4), 169.46 (C-6), 172.12 (4C=O). Anal. Calcd for C~25~H~27~ClN~4~O~11~S (627.02): C, 47.89; H, 4.34; Cl, 5.65; N, 8.94; S, 5.11. Found: C, 47.77; H, 4.26; Cl, 5.58; N, 8.86; S, 5.10%.

#### 4.3.2.7. 6-Amino-4-(2′,3′,4′,6′-tetra-O-acetyl-β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-*N*-*p*-tolyl-1,2-dihydropyrimidine-5-carboxamide (**10g**) {#sec4.3.2.7}

White solid; (EtOH), yield (88%) (method A), (85%) (method B), mp 258--259 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.98, 1.99, 2.02, 2.06 (4s, 12H, 4 × OAc), 2.66 (s, 3H, CH~3~), 4.02--4.12 (m, 2H, 2H-6′), 4.32--4.35 (m, 1H, H-5′), 4.46 (t, 1H, *J*~4′--3′~ = 3.5 Hz, *J*~4′--5′~ = 3.3 Hz, H-4′), 4.59 (t, 1H, *J*~3′--2′~ = 9.4 Hz, *J*~3′--4′~ = 3.6 Hz, H-3′), 4.68 (t, 1H, *J*~2′--1′~ = 9.6 Hz, *J*~2′--3′~ = 8.6 Hz, H-2′), 5.54 (d, 1H, *J*~1′--2′~ = 9.6 Hz, H-1′), 7.67 (s, D~2~O exch., 2H, NH~2~), 7.23--7.58 (m, 4H, C~6~H~4~), 10.68 (s, D~2~O exch., 1H, NH), 11.41 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 22.67 (4 × CH~3~), 26.34 (CH~3~), 62.18 (C-6′), 67.12 (C-5′), 68.95 (C-4′), 72.26 (C-3′), 76.22 (C-2′), 79.31 (C-1′), 92.42 (C-5), 124.25 (2C, Ar--C), 134.36 (2C, Ar--C), 138.16 (Ar--C), 140.62 (Ar--C), 160.81 (C=O), 163.44 (C=O), 165.93 (C-4), 170.26 (C-6), 172.32 (4C=O). Anal. Calcd for C~26~H~30~N~4~O~11~S (606.60): C, 51.48; H, 4.98; N, 9.24; S, 5.29. Found: C, 51.36; H, 4.90; N, 9.18; S, 5.22%.

#### 4.3.2.8. 6-Amino-*N*-(4-methoxyphenyl)-4-(2′,3′,4′,6′-tetra-1-acetyl-β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**10h**) {#sec4.3.2.8}

White solid; (EtOH), yield (87%) (method A), (82%) (method B), mp 261--262 °C; IR (KBr, cm^--1^) υ: 3378 (NH~2~), 3244 (NH), 3046 (CH aromatic), 2977 (CH), 1746 (C=O), 1671 (C=O), 1604 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.97, 1.98, 2.01, 2.05 (4s, 12H, 4xOAc), 3.91 (s, 3H, OCH~3~), 3.96--3.99 (m, 2H, 2H-6′), 4.24--4.27 (m, 1H, H-5′), 4.46 (t, 1H, *J*~4′--3′~ = 3.3 Hz, *J*~4′--5~ = 3.6 Hz, H-4′), 4.68 (t, 1H, *J*~3′--2′~ = 9.1 Hz, *J*~3′--4′~ = 9.6 Hz, H-3′), 4.92 (t, 1H, *J*~2′--1′~ = 9.6 Hz, *J*~2′--3′~ = 9.1 Hz, H-2′), 5.44 (d, 1H, *J*~1′--2′=~9.6 Hz, H-1′), 6.74 (s, D~2~O exch., 2H, NH~2~), 7.24--7.86 (m, 4H, C~6~H~4~), 10.25 (s, D~2~O exch., 1H, NH), 11.48 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 23.14 (4 × CH~3~), 55.54 (CH~3~), 62.14 (C-6′), 66.53 (C-5′), 70.82 (C-4′), 74.66 (C-3′), 76.21 (C-2′), 79.87 (C-1′), 93.23 (C-5), 123.46 (2C, Ar--C), 125.12 (2C, Ar--C), 132.83 (Ar--C), 162.16 (C=O), 164.11 (Ar--C), 165.26 (C=O), 166.92 (C-4), 168.16 (C-6), 174.16 (4C=O). Anal. Calcd for C~26~H~30~N~4~O~12~S (622.60): C, 50.16; H, 4.86; N, 9.00; S, 5.15. Found: C, 50.10; H, 4.78; N, 9.04; S, 5.12%.

4.4. General Procedure for the Synthesis of Unprotected Pyrimidine Thioglycosides (**11a**--**h**) {#sec4.4}
--------------------------------------------------------------------------------------------------

In a 50 mL Quickfit flask, tetraacetylated glycoside (10 ml) was dissolved in 20 mL of dry methanol, and then ammonia gas was allowed to pass through the solution at 0 °C for 10 min. Then, the mixture was left to stir until the reaction was completed (monitored by TLC) using CHCl~3~/MeOH 9:1. The mixture was concentrated to afford a solid residue, which was washed several times with boiling chloroform. The residue was dried, purified by column chromatography using chloroform/methanol (9:1), and crystallized from an appropriate solvent to give corresponding compounds **11a**--**h**.

### 4.4.1. 6-Amino-4-(β-[d]{.smallcaps}-glucopyranosylthio)-2-oxo-*N*-phenyl-1,2-dihydropyrimidine-5-carboxamide (**11a**) {#sec4.4.1}

White solid; (EtOH), yield (72%), mp 175 °C; IR (KBr, cm^-1^) υ: 3379 (OH), 3322, 3255 (NH~2~), 3246 (NH), 3028 (CH aromatic), 2946 (CH), 1678 (CO), 1648 (C=O), 1601 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.67--3.88 (m, 5H, H-3′, H-4′, H-5′, H-6′, H-6″), 4.19 (t, 1H, *J*~2'--1'~ = 9.1 Hz, *J*~2'--3'~ = 8.9 Hz, H-2′), 4.32 (d, 1H, *J*~1′--2′=~ 9.1 Hz, H-1′), 4.56 (t, 1H, *J*~OH′--H--6′~ = 6.1 Hz, D~2~O exch., 6′-OH), 5.12 (d, 1H, *J* = 5.6 Hz,, D~2~O exch., OH), 5.32 (d, 1H, *J* = 5.1 Hz,, D~2~O exch., OH), 5.41 (d, 1H, *J* = 4.9 Hz,, D~2~O exch., OH), 6.78 (s, D~2~O exch., 2H, NH~2~), 7.24--7.86 (m, 5H, C~6~H~5~), 9.21 (s, D~2~O exch., 1H, NH), 10.95 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 62.54 (C-6′), 70.63 (C-5′), 73.26 (C-4′), 76.67 (C-3′), 80.21 (C-2′), 82.61 (C-1′), 90.28 (C-5), 124.16 (2C, Ar--C), 131.43 (2C, Ar--C), 132.52 (Ar--C), 142.14 (Ar--C), 162.17 (C=O), 164.23 (C=O), 165.39 (C-4), 169.96 (C-6). Anal. Calcd for C~17~H~20~N~4~O~7~S (424.43): C, 48.11; H, 4.75; N, 13.20; S, 7.55. Found: C, 48.06; H, 4.68; N, 13.16; S, 7.42%.

### 4.4.2. 6-Amino-*N*-(4-chlorophenyl)-4-(β-[d]{.smallcaps}-glucopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**11b**) {#sec4.4.2}

White solid; (EtOH), yield (70%), mp 166 °C; IR (KBr, cm^-1^) υ: 3364 (OH), 3320, 3251 (NH~2~), 3251 (NH), 3036 (CH aromatic), 1678 (CO), 1664 (C=O), 1603 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.26--3.29 (m, 2H, 2H-6′), 3.44--3.45 (m, 2H, H-5′, H-4′), 3.52--3.56 (m, 1H, H-3′), 3.62 (t, 1H, *J*~2′--1′~ = 8.8 Hz, *J*~2′--3′~ = 8.2 Hz, H-2′), 4.61 (t, 1H, *J*~OH′--H--6′~ = 5.4 Hz, D~2~O exch., 6′-OH), 4.82 (d, 1H, *J* = 5.1 Hz,, D~2~O exch., OH), 5.36 (d, 1H, *J* = 6.1 Hz,, D~2~O exch., OH), 5.48 (dd, 1H, *J* = 5.2, 7.6 Hz,, D~2~O exch., OH), 5.52 (d, 1H, *J*~1′--2′=~10.8 Hz, H-1′), 6.74 (s, D~2~O exch., 2H, NH~2~), 7.36--7.89 (m, 4H, C~6~H~4~), 9.82 (s, D~2~O exch., 1H, NH), 11.44 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 62.16 (C-6′), 72.25 (C-5′), 74.18 (C-4′), 77.24 (C-3′), 80.31 (C-2′), 82.43 (C-1′), 91.28 (C-5), 123.22 (2C, Ar--C), 131.51 (2C, Ar--C), 134.62 (Ar--C), 141.72 (Ar--C), 164.15 (C=O), 165.42 (C=O), 166.24 (C-4), 168.82 (C-6). Anal. Calcd for C~17~H~19~ClN~4~O~7~S (458.87): C, 44.50; H, 4.17; Cl, 7.73; N, 12.21; S, 6.99. Found: C, 44.43; H, 4.10; Cl, 7.62; N, 12.16; S, 6.88%.

### 4.4.3. 6-Amino-4-(β-[d]{.smallcaps}-glucopyranosylthio)-2-oxo-*N*-*p*-tolyl-1,2-dihydropyrimidine-5-carboxamide (**11c**) {#sec4.4.3}

White solid; (EtOH), yield (68%), mp 169 °C; IR (KBr, cm^-1^) υ: 3352 (OH), 3327, 3259 (NH~2~), 3216 (NH), 3041 (CH aromatic), 1672 (CO), 1649 (C=O), 1598 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.32 (s, 3H, CH~3~), 3.25--3.27 (m, 2H, 2H-6′), 3.29--3.31 (m, 2H, H-5′, H-4′), 3.46 (t, 1H, *J*~3′--2′~ = 8.1 Hz, *J*~3′--4′~ = 9.1 Hz, H-3′), 3.68 (t, 1H, *J*~2′--1′~ = 9.7 Hz, *J*~2′--3′~ = 8.1 Hz, H-2′), 4.61 (t, 1H, *J*~OH′--H--6′~ = 5.4 Hz, D~2~O exch., 6′-OH), 4.91 (d, 1H, *J* = 5.3 Hz, D~2~O exch., OH), 5.24 (d, 1H, *J* = 4.8 Hz,, D~2~O exch., OH), 5.48 (dd, 1H, *J* = 4.9, 7.3 Hz,, D~2~O exch., OH), 5.54 (d, 1H, *J*~1′--2′~ = 9.7 Hz, H-1′), 6.62 (s, D~2~O exch., 2H, NH~2~), 7.24--7.47 (m, 4H, C~6~H~4~), 8.81 (s, D~2~O exch., 1H, NH), 9.68 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 28.23 (CH~3~), 62.16 (C-6′), 69.42 (C-5′), 71.51 (C-4′), 73.46 (C-3′), 75.12 (C-2′), 83.52 (C-1′), 89.62 (C-5), 121.14 (2C, Ar--C), 131.10 (2C, Ar--C), 133.35 (Ar--C), 134.22 (Ar--C), 153.37 (C=O), 156.41 (C=O), 162.68 (C-4), 172.97 (C-6). Anal. Calcd for C~18~H~22~N~4~O~7~S (438.45): C, 49.31; H, 5.06; N, 12.78; S, 7.31. Found: C, 49.25; H, 5.10; N, 12.65; S, 7.22%.

### 4.4.4. 6-Amino-*N*-(4-methoxyphenyl)-4-(β-[d]{.smallcaps}-gulcopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**11d**) {#sec4.4.4}

White solid; (EtOH), yield (65%), mp 161--162 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.91 (s, 3H, OCH~3~), 3.16--3.19 (m, 2H, 2H-6′), 3.26--3.29 (m, 2H, H-5′,H-4′), 3.48 (t, 1H, *J*~3′--2′~ = 7.9 Hz, *J*~3′--4′~ = 8.6 Hz, H-3′), 3.62 (t, 1H, *J*~2′--1′~ = 10.2 Hz, *J*~2′--3′~ = 7.9 Hz, H-2′), 4.82 (t, 1H, *J*~OH′--H--6′~ = 5.1 Hz, D~2~O exch., 6′-OH), 4.93 (d, 1H, *J* = 5.4 Hz, D~2~O exch., OH), 5.14 (d, 1H, *J* = 4.4 Hz,, D~2~O exch., OH), 5.46 (d, 1H, *J* = 5.2 Hz, D~2~O exch., OH), 5.42 (d, 1H, *J*~1′--2′~ = 10.2 Hz, H-1′), 6.58 (s, D~2~O exch., 2H, NH~2~), 7.23--7.48 (m, 4H, C~6~H~4~), 8.62 (s, D~2~O exch., 1H, NH), 9.56 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 56.97 (CH~3~), 60.81 (C-6′), 68.54 (C-5′), 72.84 (C-4′), 75.24 (C-3′), 76.65 (C-2′), 84.16 (C-1′), 92.53 (C-5), 120.23 (2C, Ar--C), 124.16 (2C, Ar--C), 134.19 (Ar--C), 157.46 (C=O), 163.45 (Ar--C), 164.96 (C=O), 167.13 (C-4), 170.62 (C-6). Anal. Calcd for C~18~H~22~N~4~O~8~S (454.45): C, 47.57; H, 4.88; N, 12.33; S, 7.06. Found: C, 47.45; H, 4.80; N, 12.24; S, 7.04%.

### 4.4.5. 6-Amino-4-(β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-*N*-phenyl-1,2-dihydropyrimidine-5-carboxamide (**11e**) {#sec4.4.5}

White solid; (EtOH), yield (60%), mp 183 °C; IR (KBr, cm^-1^) υ: 3453 (OH), 3362, 3284 (NH~2~), 3257 (NH), 3041 (CH aromatic), 2934 (CH), 1672 (CO), 1659 (C=O), 1603 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.15--3.18 (m, 2H, H-6′, H-6″), 3.22--3.27 (m, 2H, H-5′,H-4′), 3.44 (t, 1H, *J*~3′--2′~ = 8.2 Hz, *J*~3′--4′~ = 2.6 Hz, H-3′), 3.64 (t, 1H, *J*~2′--1′~ = 9.9 Hz, *J*~2′--3′~ = 8.2 Hz, H-2′), 4.48 (t, 1H, *J*~OH′−H−6′~ = 5.6, 6.0 Hz, D~2~O exch., 6′-OH), 5.04 (d, 1H, *J* = 5.7 Hz,, D~2~O exch., OH), 5.16 (d, 1H, *J* = 5.9 Hz,, D~2~O exch., OH), 5.34 (d, 1H, *J* = 6.1 Hz,, D~2~O exch., OH), 5.43 (d, 1H, *J*~1′--2′=~9.9 Hz, H-1′), 6.64 (s, D~2~O exch., 2H, NH~2~), 7.14--7.47 (m, 5H, C~6~H~5~), 9.98 (s, D~2~O exch., 1H, NH), 10.35 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 61.35 (C-6′), 68.26 (C-5′), 70.11 (C-4′), 74.27 (C-3′), 77.34 (C-2′), 80.45 (C-1′), 89.24 (C-5), 123.17 (2C, Ar--C), 130.22 (2C, Ar--C), 132.61 (Ar--C), 141.21 (Ar--C), 161.25 (C=O), 160.41 (C=O), 163.21 (C-4), 168.15 (C-6). Anal. Calcd for C~17~H~20~N~4~O~7~S (424.43): C, 48.11; H, 4.75; N, 13.20; S, 7.55. Found: C, 48.06; H, 4.68; N, 13.16; S, 7.42%.

### 4.4.6. 6-Amino-*N*-(4-chlorophenyl)-4-(β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**11f**) {#sec4.4.6}

White solid; (EtOH), yield (64%), mp 172 °C; IR (KBr, cm^-1^) υ: 3379 (OH), 3353 (NH~2~), 3262 (NH), 3039 (CH aromatic), 1667 (CO), 1654 (C=O), 1595 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.24--3.26 (m, 2H, 2H-6′), 3.41--3.43 (m, 1H, H-5′), 3.54 (t, 1H, *J*~4′--3′~ = 2.3 Hz, *J*~4′--5′~ = 2.6 Hz, H-4′), 3.56 (t, 1H, *J*~3′--2′~ = 8.2 Hz, *J*~3′--4′~ = 2.3 Hz, H-3′), 3.68 (t, 1H, *J*~2′--1′~ = 10.6 Hz, *J*~2′--3′~ = 9.4 Hz, H-2′), 4. 51 (t, 1H, *J*~OH′--H--6′~ = 6.1 Hz, D~2~O exch., 6′-OH), 4.76 (d, 1H, *J* = 5.7 Hz, D~2~O exch., OH), 4.92 (d, 1H, *J* = 6.2 Hz,, D~2~O exch., OH), 5.38 (d, 1H, *J* = 6.0, Hz, D~2~O exch., OH), 5.54 (d, 1H, *J*~1′--2′=~10.6 Hz, H-1̀), 6.69 (s, D~2~O exch., 2H, NH~2~), 7.25--7.57 (m, 4H, C~6~H~4~), 9.68 (s, D~2~O exch., 1H, NH), 10.53 (s, D~2~O exch., 1H, NH); Anal. Calcd for C~17~H~19~ClN~4~O~7~S (458.87): C, 44.50; H, 4.17; Cl, 7.73; N, 12.21; S, 6.99. Found: C, 44.43; H, 4.10; Cl, 7.62; N, 12.16; S, 6.88%.

### 4.4.7. 6-Amino-4-(β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-*N*-*p*-tolyl-1,2-dihydropyrimidine-5-carboxamide (**11g**) {#sec4.4.7}

White solid; (EtOH), yield (66%), mp 174 °C; IR (KBr, cm^-1^) υ: 3373 (OH), 3356 (NH~2~), 3243 (NH), 3037 (CH aromatic), 1669 (CO), 1655 (C=O), 1597 (C=N); ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.36 (s, 3H, CH~3~), 3.26--3.28 (m, 2H, 2H-6′), 3.30--3.31 (m, 2H, H-5′, H-4′), 3.44 (t, 1H, *J*~3′--2′~ = 8.6 Hz, *J*~3′--4′~ = 3.1 Hz, H-3′), 3.57 (t, 1H, *J*~2′--1′~ = 9.6 Hz, *J*~2′--3′~ = 8.6 Hz, H-2′), 4.66 (t, 1H, *J*~OH′--H--6′~ = 5.6 Hz, D~2~O exch., 6′-OH), 4.82 (d, 1H, *J* = 6.2 Hz, D~2~O exch., OH), 5.10 (d, 1H, *J* = 4.5 Hz,, D~2~O exch., OH), 5.31 (d, 1H, *J* = 4.9, Hz,, D~2~O exch., OH), 5.54 (d, 1H, *J*~1′--2′=~9.6 Hz, H-1′), 6.84 (s, D~2~O exch., 2H, NH~2~), 7.23--7.46 (m, 4H, C~6~H~4~), 8.65 (s, D~2~O exch., 1H, NH), 9.92 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 29.41 (CH~3~), 60.24 (C-6′), 69.17 (C-5′), 72.32 (C-4′), 75.35 (C-3′), 77.54 (C-2′), 81.23 (C-1′), 90.34 (C-5), 120.52 (2C, Ar--C), 131.44 (2C, Ar--C), 132.27 (Ar--C), 136.13 (Ar--C), 152.27 (C=O), 155.29 (C=O), 163.74 (C-4), 169.21 (C-6). Anal. Calcd for C~18~H~22~N~4~O~7~S (438.45): C, 49.31; H, 5.06; N, 12.78; S, 7.31. Found: C, 49.25; H, 5.10; N, 12.65; S, 7.22%.

### 4.4.8. 6-Amino-*N*-(4-methoxyphenyl)-4-(β-[d]{.smallcaps}-galactopyranosylthio)-2-oxo-1,2-dihydropyrimidine-5-carboxamide (**11h**) {#sec4.4.8}

White solid; (EtOH), yield (63%), mp 157--158 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.96 (s, 3H, OCH~3~), 3.2--3.24 (m, 2H, 2H-6′), 3.28--3.01 (m, 1H, H-5′), 3.46 (t,1H, *J*~4′--3′~ = 3.1 Hz, *J*~4′--5′~ = 2.5 Hz, H-4′), 4.02 (t, 1H, *J*~3′--2′~ = 8.7 Hz, *J*~3′--4′~ = 3.1 Hz, H-3′), 4.23 (t, 1H, *J*~2′--1′~ = 10.6 Hz, *J*~2′--3′~ = 8.7 Hz, H-2′), 4.75 (t, 1H, *J*~OH′--H--6′~ = 6.1 Hz, D~2~O exch., 6′-OH), 4.88 (d, 1H, *J* = 5.8 Hz, D~2~O exch., OH), 4.95 (d, 1H, *J* = 5.6 Hz,, D~2~O exch., OH), 5.21 (d, 1H, *J* = 6.3 Hz, D~2~O exch., OH), 5.41 (d, 1H, *J*~1′--2′~ = 10.6 Hz, H-1′), 6.91 (s, D~2~O exch., 2H, NH~2~), 7.23--7.81 (m, 4H, C~6~H~4~), 9.82 (s, D~2~O exch., 1H, NH), 10.24 (s, D~2~O exch., 1H, NH); ^13^C NMR: δ 32.45 (CH~3~), 61.83 (C-6′), 69.66 (C-5′), 72.23 (C-4′), 75.22 (C-3′), 77.45 (C-2′), 83.84 (C-1′), 91.25 (C-5), 122.16 (2C, Ar--C), 132.73 (2C, Ar--C), 134.11 (Ar--C), 135.92 (Ar--C), 153.88 (C=O), 155.65 (C=O), 164.26 (C-4), 173.26 (C-6). Anal. Calcd for C~18~H~22~N~4~O~8~S (454.45): C, 47.57; H, 4.88; N, 12.33; S, 7.06. Found: C, 47.48; H, 4.79; N, 12.25; S, 7.16%.

4.5. Cytotoxicity Assay {#sec4.5}
-----------------------

Antiviral activity assay and MTT cytotoxicity assay (TC50). Samples were 10-fold serially diluted with Dulbecco's modified Eagle's medium (DMEM). Standard solutions of the compounds under investigation were prepared in 10% dimethyl sulfoxide (DMSO). The cytotoxic effect of the resulting extracts was tested in Madin Darby Canine kidney (MDCK) cells by using the MTT method (Mosmann, 1983).^[@ref28]^ Briefly, the cells were seeded in 96-well plates (100 μL/well at a density of 3 × 10^5^ cells/mL) and incubated for 24 h at 37 °C in 5% CO~2~. After 24 h, different concentrations of the examined compounds were applied to the cells in triplicate, the plates were left for another 24 h, the supernatant was discarded, cell monolayers were washed with sterile phosphate buffer saline three times, and the MTT solution (20 μL of 5 mg/mL stock solution) was added to each well and incubated at 37 °C for 4 h, followed by medium aspiration. In each well, the formed formazan crystals were dissolved in 200 μL of acidified isopropanol (0.04 M HCl in absolute isopropanol = 0.073 mL HCL in 50 mL of isopropanol). The absorbance values at λ max 540 and 620 nm were measured for the formazan solution and stated as a reference wavelength using a multiwell plate reader. The ratio of cytotoxicity with respect to the untreated cells was determined. The plot of cytotoxicity percentage versus sample concentration was used to calculate the concentration, which revealed 50% cytotoxicity (LD50).

4.6. Plaque Reduction Assay {#sec4.6}
---------------------------

The technique of (Hayden et al., 1980)^[@ref29]^ was used to accomplish this test in a six-well plate. MDCK cells (10^5^ cells/mL) were cultivated for 24 h at 37 °C. A/CHICKEN/7217B/1/2013 (H5N1) virus was diluted to make 10^5^ PFU/forming homogeneous solution with the safe concentration of the compounds under test and then incubated for 30 min at 37 °C before being applied to the cells. The growth medium was removed from the cell culture plates and virus-Cpd or virus-extract and Virus-oseltamivir mixtures were inoculated (100 μL/well) for 1 h contact time to achieve virus adsorption. A mixture of 3 mL of DMEM supplemented and 2% agarose was poured onto the cell monolayer, and plates were left to solidify and incubated at 37 °C until the formation of viral plaques (3--4 days). An alcoholic solution of Formalin (10%) was added, and then after 2 h plates were marked with 0.1% crystal violet in distilled water. Control wells were included where untreated virus was incubated with MDCK cells, and finally, plaques were counted. The percentage reduction in plaque formation in comparison to control wells was recorded.
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